Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Avapritinib

FDA-approved product (tablet, oral), marketed as Ayvakit.

Registered studies
30
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Avapritinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Gastrointestinal stromal tumor
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

30registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Avapritinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Avapritinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

    NCT07264959 · start 2026-04-15

    Registered record
    Registry ID
    NCT07264959
    Conditions
    Indolent Systemic Mastocytosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-04-15
    Completion
    2032-12-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIndolent Systemic Mastocytosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

    NCT07255638 · start 2025-12-09

    Registered record
    Registry ID
    NCT07255638
    Conditions
    Indolent Systemic Mastocytosis
    Interventions
    Avapritinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-12-09
    Completion
    2028-12-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIndolent Systemic Mastocytosis
    InterventionAvapritinib
    PhaseNot recorded
    Registry statusRecruiting

  • A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia

    NCT07028073 · start 2025-05-15

    Registered record
    Registry ID
    NCT07028073
    Conditions
    Acute Myeloid Leukemia With T(8; 21)(Q22; Q22); Acute Myeloid Leukemia With T(16; 16)(P13; Q22); KIT Gene Mutation; Avapritinib
    Interventions
    Group A (FIT): Avapritinib + IA regimen; Group B (UNFIT): Avapritinib + VA regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-05-15
    Completion
    2027-12-31
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia With T(8; 21)(Q22; Q22); Acute Myeloid Leukemia With T(16 +4 more
    InterventionGroup A (FIT): Avapritinib + IA regimen; Group B (UNFIT): Avapritinib + VA regimen
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Avapritinib Maintenance for AML With KIT Mutations

    NCT06765915 · start 2025-02-01

    Registered record
    Registry ID
    NCT06765915
    Conditions
    AML, Adult
    Interventions
    Avapritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-02-01
    Completion
    2028-02-01
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML, Adult
    InterventionAvapritinib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

    NCT06783790 · start 2025-01-20

    Registered record
    Registry ID
    NCT06783790
    Conditions
    AML (Acute Myelogenous Leukemia)
    Interventions
    Avapritinib, azacitidine, Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-01-20
    Completion
    2027-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML (Acute Myelogenous Leukemia)
    InterventionAvapritinib, azacitidine, Venetoclax
    PhasePhase 2
    Registry statusRecruiting

  • Avapritinib Rollover Study

    NCT06748001 · start 2024-11-28

    Registered record
    Registry ID
    NCT06748001
    Conditions
    Mastocytosis, Systemic
    Interventions
    Avapritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-11-28
    Completion
    2027-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMastocytosis, Systemic
    InterventionAvapritinib
    PhasePhase 4
    Registry statusRecruiting

  • MRD-positive AML Clinical Study

    NCT07131059 · start 2024-05-11

    Registered record
    Registry ID
    NCT07131059
    Conditions
    AML, Adult
    Interventions
    Ivosidenib; Gilteritinib; Venetoclax; Avapritinib; Daunorubicin; Cytarabine; Idarubicin; Mitoxantrone; Homoharringtonine; Azacitidine; Ruxolitinib; Trametinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-05-11
    Completion
    2028-10-30
    Enrolment
    537

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML, Adult
    InterventionIvosidenib; Gilteritinib; Venetoclax; Avapritinib +8 more
    PhaseNot applicable
    Registry statusRecruiting

  • Avapritinib With Decitabine in Patients With SM-AHN

    NCT06327685 · start 2024-03-13

    Registered record
    Registry ID
    NCT06327685
    Conditions
    Systemic Mastocytosis With an Associated Hematologic Neoplasm
    Interventions
    Avapritinib; Decitabine; Decitabine/Cedazuridine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-03-13
    Completion
    2027-03
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Mastocytosis With an Associated Hematologic Neoplasm
    InterventionAvapritinib; Decitabine; Decitabine/Cedazuridine
    PhasePhase 1
    Registry statusRecruiting

  • Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

    NCT06316960 · start 2024-03-01

    Registered record
    Registry ID
    NCT06316960
    Conditions
    AML, Childhood; Relapse/Recurrence; Refractory AML; Core Binding Factor Acute Myeloid Leukemia; C-KIT Mutation
    Interventions
    Avapritinib; Azacitidine Injection; Decitabine Injection; Idarubicin Hydrochloride; Cytarabine; Granulocyte Colony-Stimulating Factor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-03-01
    Completion
    2027-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML, Childhood; Relapse/Recurrence; Refractory AML; Core Binding Factor Acute Myeloid Leukemia +1 more
    InterventionAvapritinib; Azacitidine Injection; Decitabine Injection; Idarubicin Hydrochloride +2 more
    PhasePhase 2
    Registry statusRecruiting

  • Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

    NCT06221683 · start 2024-01-01

    Registered record
    Registry ID
    NCT06221683
    Conditions
    AML, Childhood; Acute Myeloid Leukemia
    Interventions
    Homoharringtonine; Cytarabine; Etoposide; Venetoclax; Mitoxantrone hydrochloride liposome; Recombinant Human Granulocyte Colony-Stimulating Factor; Idarubicin Hydrochloride; Sorafenib; Gilteritinib; Avapritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-01-01
    Completion
    2029-12
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML, Childhood; Acute Myeloid Leukemia
    InterventionHomoharringtonine; Cytarabine; Etoposide; Venetoclax +6 more
    PhasePhase 2
    Registry statusRecruiting

  • Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World

    NCT05381753 · start 2022-08-29

    Registered record
    Registry ID
    NCT05381753
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Avapritinib; Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-08-29
    Completion
    2024-09-30
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionAvapritinib; Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
    PhaseNot recorded
    Registry statusCompleted

  • A Drug-drug Interaction Study of Avapritinib and Midazolam

    NCT04908176 · start 2022-08-24

    Registered record
    Registry ID
    NCT04908176
    Conditions
    Gastrointestinal Stromal Tumors; GIST; Non-resectable Advanced Solid Tumors; Recurrent or Unresectable Central Nervous System (CNS) Tumors
    Interventions
    Avapritinib; midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-08-24
    Completion
    2024-05-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors; GIST; Non-resectable Advanced Solid Tumors; Recurrent or Unresectable Central Nervous System (CNS) Tumors
    InterventionAvapritinib; midazolam
    PhasePhase 1
    Registry statusCompleted

  • Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA

    NCT05461664 · start 2022-07-10

    Registered record
    Registry ID
    NCT05461664
    Conditions
    Gastrointestinal Stromal Tumors; Unresectable Solid Tumor; Recurrent Metastatic Malignant Neoplasm
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-07-10
    Completion
    2025-12-31
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors; Unresectable Solid Tumor; Recurrent Metastatic Malignant Neoplasm
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors

    NCT05464875 · start 2022-07-09

    Registered record
    Registry ID
    NCT05464875
    Conditions
    Gastrointestinal Stromal Tumors; Unresectable Solid Tumor; Recurrent Metastatic Malignant Neoplasm
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-07-09
    Completion
    2025-12-31
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors; Unresectable Solid Tumor; Recurrent Metastatic Malignant Neoplasm
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Avapritinib in CBF-AML With KIT Mutations

    NCT05821738 · start 2022-06-01

    Registered record
    Registry ID
    NCT05821738
    Conditions
    Core Binding Factor Acute Myeloid Leukemia; KIT Mutation-Related Tumors
    Interventions
    Avapritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-06-01
    Completion
    2025-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCore Binding Factor Acute Myeloid Leukemia; KIT Mutation-Related Tumors
    InterventionAvapritinib
    PhasePhase 2
    Registry statusUnknown